Summary
From considerations of hepatic physiology and pathology coupled with pharmacokinetic principles, it appears that altered drug elimination in liver disease may result from the following mechanisms: reduction in absolute cell mass, in cellular enzyme content and/or activity, in portal vein perfusion due to extrahepatic/intrahepatic shunting, or of portal perfusion of hepatocyte mass due to decreased portal flow or sinusoidal perfusion; increase in arterial perfusion relative to portal perfusion; preferential perfusion of the sinusoidal midzone and terminal zones by arterioles; potential for direct mixing of arterial blood within the space of Disse; reduced exchange across the endothelial lining; and impaired diffusion within the space of Disse.
In general, oxidative drug metabolism is impaired in liver disease and the degree of impairment of oxidisation differs between drugs but correlates best with the degree of sinusoidal capillarisation, i.e. the degree of access of the drug from the sinusoid to the hepatocyte. Drug conjugation appears to be relatively unaffected by liver disease, whereas elimination by biliary excretion correlates best with the degree of intrahepatic shunting and not with sinusoidal capillarisation. As the latter should impair hepatocyte access of all compounds similarly, a potentially important mechanism could be impaired access of oxygen to hepatocytes as oxidative metabolism is much more sensitive to oxygen supply than are conjugation or biliary excretion. This suggests a potentially important therapeutic role for agents which increase the hepatic oxygen supply.
Useful adjunctive strategies may also derive from the oxygen limitation hypothesis. Anaemia should be targeted as a critically important variable, as should oxygen-carrying capacity, i.e. modification of the smoking habit. Additionally, enzyme inducers such as barbiturates may be used if overriding hypoxic constraints are removed by oxygen supplementation. Agents likely to seriously compromise arterial perfusion of the hepatic vascular bed should be avoided, e.g. those causing postural hypotension or vasospasm. Vasodilators can be used to actively promote arterial perfusion.
While the effect of liver disease on drug handling is highly variable and difficult to predict, there are well recognised principles for modifying dosage. These include halving the dose of drugs given systemically (or of low clearance drugs given orally) and a 50 to 90% reduction in the dose of drugs with a high hepatic clearance given orally. Changes in the pharmacodynamic effects of drugs (either alone or in addition to pharmacokinetic changes) can also be profound, and awareness of this possibility should be increased.
Article PDF
Similar content being viewed by others
References
Acocella G, Bonollo L, Garimoldi M, Mainardi M, Tenconi LT, et al. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 13: 47–53, 1972
Aguirre C, Calvo R, Rodriguez-Sasiain JM. Serum protein binding of penbutolol in patients with hepatic cirrhosis. International Journal of Clinical Pharmacology, Therapy and Toxicology 26: 566–569, 1988
Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Medica Scandinavica (Suppl. 624): 99–105, 1979
Angus PW, Mihaly GW, Morgan DJ, Smallwood RA. Oxygen dependence of omeprazole clearance and sulphone and sulphide metabolite formation in the isolated perfused rat liver. Journal of Pharmacology and Therapeutics 250: 1043–1047, 1989a
Angus PW, Mihaly GW, Morgan DJ, Smallwood RA. Oxygen dependence of salbutamol elimination by the isolated perfused rat liver. Biochemical Pharmacology 38: 1443–1449, 1989b
Aw TK, Jones DP. Secondary bioenergetic hypoxia. Inhibition of sulfation and glucuronidation reactions in isolated hepatocytes at low O2 concentration. Journal of Biological Chemistry 219: 8997–9004, 1982
Babbs CB, Haboubi NY, Mellor JM, Smith A, Rowan BP, et al. Endothelial cell transformation in primary biliary cirrhosis: A morphological and biochemical study. Hepatology 11: 723–729, 1990
Bakti G, Fisch HU, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 7: 629–638, 1987
Ballett F. Hepatic circulation: potential for therapeutic intervention. Pharmacology and Therapeutics 47: 281–328, 1990
Barbare JC, Poupon RE, Jaillon P, Prod’homme S, Darnis F, et al. Intrinsic hepatic clearance and Child-Turcotte classification for assessment of liver function in cirrhosis. Journal of Hepatology 1: 253–259, 1985
Barre J, Mallet A, Rosenbaum J, Deforges L, Houin G, et al. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. British Journal of Clinical Pharmacology 23: 753–757, 1987
Bass NM, Williams RL. Guide to drug dosage in hepatic disease. Clinical Pharmacokinetics 15: 396–420, 1988
Benson GD. Acetaminophen in chronic liver disease. Clinical Pharmacology and Therapeutics 33: 95–101, 1983
Bergstrand RH, Wang T, Roden DM, Avant GR, Sutton WW, et al. Encainide disposition in patients with chronic cirrhosis. Clinical Pharmacology and Therapeutics 40: 148–154, 1986
Biou D, Konan D, Feger J, Agneray J, Leroy Y, et al. Alterations in the carbohydrate moiety of alpha-1-acid glycoprotein purified from human cirrhotic ascitic fluid. Biochimica et Biophysica Acta 912: 308–312, 1987
Birnie GG, McColl KEL, Thompson GG, Moore MR, Goldberg A, et al. Antipyrine metabolism in acute hepatic porphyria in relapse and remission. British Journal of Clinical Pharmacology 23: 358–361, 1987
Blaschke TF. Protein binding and kinetics of drugs in liver disease. Clinical Pharmacokinetics 2: 32–44, 1977
Blaschke TF, Rubin PC. Hepatic first-pass metabolism in liver disease. Clinical Pharmacokinetics 4: 423–432, 1979
Blei AT. Pharmacokinetic-hemodynamic interactions in cirrhosis. Seminars in Liver Disease 6: 299–308, 1986
Branch RA. Drugs as indicators of hepatic function. Hepatology 2: 97–105, 1982
Branch RA, Morgan MH, James J, Read AE. Intravenous administration of diazepam in patients with chronic liver disease. Gut 17: 975–983, 1976
Branch RA, Shand DG. Propranolol disposition in chronic liver disease: a physiological approach. Clinical Pharmacokinetics 1: 264–279, 1976
Breen KJ, Bury RW, Calder I, Desmond PV, Peters M, et al. A [14C]-phenacetin breath test to measure hepatic function in man. Hepatology 4: 47–52, 1984
Brodie MJ, Boobis AR, Bulpitt CJ, Davies DS. Influence of liver disease and environmental factors on hepatic monoxygenase activity in vitro. European Journal of Clinical Pharmacology 20: 39–46, 1981
Brody DH, Leichter L. Clearance tests of liver function. Medical Clinics of North America 63: 621–630, 1979
Brosen K. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clinical Pharmacokinetics 18: 220–239, 1990
Brunner G, von Bergmann K, Hacker W, von Mollendorff E. Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzneimittel-Forschung 38: 176–179, 1988
Butterworth RF, Lavoie J, Giguere JF, Pomier-Layrargues G. Affinities and densities of high affinity [3H] muscimol (GABAA) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 8: 1084–1088, 1988
Byrne AJ, Morgan DJ, Harrison PM, McLean AJ. Variation in hepatic extraction rate with unbound drug fraction: discrimination between models of hepatic drug elimination. Journal of Pharmaceutical Sciences 74: 205–207, 1985
Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clinical Science 21: 43–57, 1961
Campra JL, Reynolds TB. The hepatic circulation. In Arias et al. (Eds) The liver: biology and pathobiology, pp. 627–646, Raven Press, New York, 1982
Cantrill E, Murray M, Mehta I, Farrell GC. Downregulation of the male-specific hepatic microsomal steroid 16a-hydroxylose, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis. Journal of Clinical Investigation 83: 1211–1216, 1989
Caujolle B, Ballet F, Poupon R. Relationships among beta-adrenergic blockade, propranolol concentration, and liver function in patients with cirrhosis. Scandinavian Journal of Gastroenterology 23: 925–930, 1988
Cello JP, Øie S. Cimetidine disposition in patients with Laennec’s cirrhosis during multiple dosing therapy. European Journal of Clinical Pharmacology 25: 223–229, 1983
Cherrick GR, Stein SW, Leevy CM, Davidson CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. Journal of Clinical Investigation 39: 592–600, 1960
Colli A, Buccino G, Cocciolo M, Parravicini R, Scaltrino G. Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. Clinical Pharmacology and Therapeutics 44: 642–649, 1988
Crotty B, Watson KJR, Desmond PV, Mashford ML, Wood LJ, et al. Hepatic extraction of morphine is impaired in cirrhosis. European Journal of Clinical Pharmacology 36: 501–506, 1989
Daneshmend TK, Homeida M, Kaye CM, Elamin AA, Roberts CJC. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis in hepatic cirrhosis and in hepatosplenic schistosomiasis. Gut 23: 807–813, 1982
Dao MT, VIlleneuve J-P. Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis. Clinical and Investigative Medicine 11: 6–9, 1988
Davey PG. Pharmacokinetics in liver disease. Journal of Antimicrobial Chemotherapy 21: 1–8, 1988
Desmond PV, Patwardhan RV, Johnson RF, Schenker S. Impaired elimination of caffeine in cirrhosis. Digestive Diseases and Science 25: 193–197, 1980
Dunn MA, Kamal R. Hepatic schistosomiasis. Hepatology 1: 653–661, 1981
Du Souich P, Erill S. Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease. Clinical Pharmacology and Therapeutics 22: 588–595, 1977
Echizen H, Ishizaki T. Superiority of disease-specific over conventional formula in predicting creatinine clearance from serum creatinine in patients with liver cirrhosis. Therapeutic Drug Monitoring 10: 369–375, 1988
Erlinger S. What is cholestasis in 1985? Journal of Hepatology 1: 687–693, 1985
Farrell GC, Cooksley WGE, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolising enzymes. Clinical Pharmacology and Therapeutics 26: 483–492, 1979
Farrell GC, Koltai A, Murray M. Source of raised serum estrogens in male rats with portal bypass. Journal of Clinical Investigation 81: 221–228, 1988
Farrell GC, Zaluzny L. Portal vein ligation selectively lowers hepatic cytochrome P450 levels in rats. Gastroenterology 85: 275–282, 1983
Forrest JAH, Andriaenssens P, Finlayson NDC, Prescott LF. Paracetamol metabolism in chronic liver disease. European Journal of Clinical Pharmacology 15: 427–431, 1979
Forrest JAH, Finlayson NDC, Adjepon-Yamoah KK, Prescott LF. Antipyrine, paracetamol and lignocaine elimination in chronic liver disease. British Medical Journal 1: 1384–1387, 1977
Frost RW, Lettieri JT, Krol G, Shamblen EC, Lesseter KL. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciproflaxin. Clinical Pharmacology and Therapeutics 45: 608–616, 1989
Fuller R, Hoppel C, Ingalls ST. Furosemide kinetics in patients with hepatic cirrhosis with ascites. Clinical Pharmacology and Therapeutics 30: 461–467, 1981
Gengo FM, Fagan SC, Krol G, Bernhard H. Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls. British Journal of Clinical Pharmacology 23: 46–53, 1987
Gerbes AL, Remien J, Jungst D, Sauerbruch Y, Paumgartner G. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1: 1409–1411, 1986
Ghabrial H, Desmond PV, Watson KJR, Gijsbers AJ, Horman PJ, et al. The effects of age and chronic liver disease on the elimination of temazepam. European Journal of Clinical Pharmacology 30: 93–97, 1986
Giacomini KM, Giacomini JC, Gibson TP, Levy G. Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt. Clinical Pharmacology and Therapeutics 28: 417–424, 1980
Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacology and Therapeutics 45: 1–38, 1990
Gonzalez G, Aransibia A, Rivas MI, Caro P, Antezana C. Pharmacokinetics of frusemide in patients with hepatic cirrhosis. European Journal of Clinical Pharmacology 22: 315–320, 1982
Goresky CA. A linear method for determining liver sinusoidal and extracellular volume. American Journal of Physiology 204: 626–640, 1963
Goresky CA, Bach GG, Nadeau BE. On the uptake of material by the intact liver: the transport and net removal of galactose. Journal of Clinical Investigation 52: 991–1009, 1973
Goresky CA, Ziegler WH, Bach GG. Capillary exchange modelling. Barrier-limited and flow-limited distribution. Circulation Research 27: 739–764, 1970
Grahnen A, Jameson S, Loof L, Tyllstrom J, Lindstrom B. Pharmacokinetics of cimetidine in advanced cirrhosis. European Journal of Clinical Pharmacology 26: 347–355, 1984
Greenway CV, Stark RD. Hepatic vascular bed. Physiological Reviews 51: 23–65, 1971
Gross JB, Reichen J, Zeltner TB, Zimmermann A. The evolution of changes in quantitative liver function tests in a rat model of biliary cirrhosis: correlation with morphometric measurement of hepatocyte mass. Hepatology 7: 457–463, 1987
Groszmann R, Kotelanski B, Cohn JN, Khatri IM. Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. American Journal of Medicine 53: 715–722, 1972
Groszmann RJ, Kravetz O, Paryzow O. Arteriovenous (AV) shunting in the liver. Gastroenterolopy 70: 983, 1976
Groszmann RJ, Kravetz O, Paryzow O. Intrahepatic arteriovenous shunting in cirrhosis of the liver. Gastroenterology 73: 201–204, 1977
Guechot J, Loric S, Vaubourdolle M, Chretien Y, Giboudeau J, et al. Effect of protein binding on testosterone extraction by human cirrhotic liver: evidence for a dissociation-limited uptake. Journal of Clinical Endocrinology and Metabolism 69: 200–203, 1989
Guengerich FP. Characterization of human microsomal cytochrome P-450 enzymes. Annual Review of Pharmacology and Toxicology 29: 241–264, 1989
Gugler R, Muller-Liebenau B, Somogyi A. Altered disposition of cimetidine in liver cirrhotic patients. British Journal of Clinical Pharmacology 14: 421–429, 1982
Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, et al. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. British Journal of Clinical Pharmacology 29: 289–297, 1990
Heinzow B, Corbett H, Constantinides S, Bourne R, McLean AJ. Interaction between oral hydralazine and propranolol I. Changes in absorption, presystemic clearance and splanchnic blood flow. Journal of Pharmacology and Experimental Therapeutics 229: 509–514, 1984
Henderson JM, Kutner MH, Bain RP. First-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 83: 1090–1096, 1982
Hepner GW, Vesell ES. Assessment of aminopyrine metabolism in man after administration of 14C-aminopyrine. Effects of phenobarbital, disulfram and portal cirrhosis. New England Journal of Medicine 291: 1384–1388, 1974
Hepner GW, Vesell ES, Lipton A, Harvey HA, Wilkinson GR, et al. Disposition of aminopyrine, antipyrine, diazepam and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. Journal of Laboratory and Clinical Medicine 90: 440–456, 1977
Hoefs J, Sakimura I, Reynolds T. Direct measurement of intrahepatic shunting by the portal vein injection of mirospheres. Gastroenterology 75: 968, 1978
Holazo AO, Chen SS, McMahon FG, Ryan JR, Konikoff JJ, et al. The influence of liver dysfunction on the pharmacokinetics of carprofen. Journal of Clinical Pharmacology 25: 109–114, 1985
Holstege A, Staiger M, Haag K, Gerok W. Correlation of caffeine elimination and Child’s classification in liver cirrhosis. Klinische Wochenschrift 67: 6–15, 1989
Homeida MMA, Ali HM, Arbab BMO, Harron DWG. Propranliver disease: can we expect to find a universal, quantitative marker of hepatic function? Hepatology 10: 893–895, 1989
Morgan MY, Stambuk D. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study. Postgraduate Medical Journal 62 (Suppl. 2): 29–37, 1986
Morichau-Beauchant M, Hauin G, Mavier P, Alexandre C, Dhumeaux D. Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients. Digestive Diseases and Sciences 31: 113–118, 1986
Murray M, Zaluzny L, Farrell GC. Drug metabolism in cirrhosis. Selective changes in cytochrome P450 isozymes in the cholinedeficient rat model. Biochemical Pharmacology 35: 1817–1824, 1986
Narang APS, Datta DV, Nath N, Mathur VS. Pharmacokinetic study of chloramphenicol in patients with liver disease. European Journal of Clinical Pharmacology 20: 479–483, 1981
Neal EA, Meffin PJ, Gregory PB, Blaschke TF. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 77: 96–102, 1979
Ochs HR, Greenblatt DJ, Verburg-Ochs B, Matlis R. Temazepam clearance unaltered in cirrhosis. American Journal of Gastroenterology 81: 80–84, 1986
Oellerich M, Burdelski M, Lautz H-U, Schultz M, Schmidt F-W, et al. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Therapeutic Drug Monitoring 12: 219–226, 1990
Ohkubo H, Okuda K, Iida S, Ohnishi K, Ikawa S, et al. Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology 86: 514–520, 1984
Ohnishi A, Tsuboi Y, Ishizaki T, Kubota K, Ohno T, et al. Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clinical Pharmacology and Therapeutics 45: 657–665, 1989
Pacifici GM, Viana A, Franchi M, Santerini S, Temellini A, et al. Conjugation pathways in liver disease. British Journal of Clinical Pharmacology 30: 427–435, 1990
Pang KS, Rowland M. Hepatic clearance of drugs: 1. Theoretical considerations of a ‘well-stirred’ model and a ‘parallel’ model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics and Biopharmaceutics 5: 625–653, 1977
Papadakis MA, Arief AI. Unpredictability of clinical evaluation of renal function in cirrhosis. American Journal of Medicine 82: 945–952, 1987
Papper S. Hepatorenal syndrome. In Epstein (Ed.) The kidney in liver disease, 2nd ed., pp. 87–106, Elsevier Biomedical, New York, 1983
Patwardhan RV, Johnson RF, Hoyumpa A, Sheenan JJ, Desmond PV, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology 81: 1006–1011, 1981
Pedersen LE, Bonde J, Graudal NA, Backer NV, Hansen JES, et al. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function. British Journal of Clinical Pharmacology 23: 41–46, 1987
Pentikainen PJ, Hietakorpi S, Halinen MO, Lampinen LM. Cirrhosis of the liver markedly impairs the elimination of mexiletine. European Journal of Clinical Pharmacology 30: 83–88, 1986
Pentikainen PJ, Valisalmi L, Himberg JJ, Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. Journal of Clinical Pharmacology 29: 272–277, 1989
Pessayre D, Lebrec D, Descatoire V, Peignoux M, Benhamou J-P. Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology 74: 566–571, 1978
Plourde V, Gascon-Barré M, Coulombe PA, Vallires S, Huet P-M. Hepatic handling of vitamin D3 in micronodular cirrhosis: a structure-function study in the rat. Journal of Bone and Mineral Research 3: 461–471, 1988
Pomier-Layrargues G, Giguere JF, Lavoie J, Willems B, Butterworth RF. Pharmacokinetics of benzodiazepine antagonist Ro15-1788 in cirrhotic patients with moderate or severe liver dysfunction. Hepatology 10: 969–972, 1989
Pomier-Layrargues G, Huet PM, Villeneuve JP, Marleau D. Effect of portacaval shunt on drug disposition in patients with cirrhosis. Gastroenterology 91: 163–167, 1986
Popper H, Elias H, Petty DE. Vascular pattern of the cirrhotic liver. American Journal of Clinical Pathology 22: 717–729, 1952
Poupon RE, Poupon RY, Dumont M, Erlinger S, Hepatic storage and biliary transport maximum of taurocholate and tauro-cheno desoxycholate in the dog. European Journal of Clinical Investigation 6: 431–437, 1976
Poupon RY, Poupon RE, Lebrec D, Quernec LL, Darnis F. Mechanisms for reduced hepatic clearance and elevated plasma levels of bile acids in cirrhosis: a study in patients with an end-to-side portacaval shunt. Gastroenterology 80: 1438–1444, 1981
Ramond M-J, Comoy E, Lebrec D. Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity. British Journal of Clinical Pharmacology 21: 191–196, 1986
Ramzan IM, Yasuhara M, Levy G. Kinetics of drug action in disease states: XIX. Effect of experimental liver disease on the neurotoxicity of theophylline in rats. Journal of Pharmacology and Experimental Therapeutics 241: 236–238, 1987
Reichen J. Hepatic spaces and transport in the liver. In Petzinger et al. (Eds) Hepatic transport in organic substances, pp. 45–56, Springer-Verlag, Berlin 1989
Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology 11: 1066–1078, 1990
Reichen J, Arts B, Schafroth U, Zimmerman A, Zeltner T, et al. Aminopyrine N-demethylation by rats with liver cirrhosis: evidence for the intact cell hypothesis. A morphometric-functional study. Gastroenterology 93: 719–726, 1987a
Reichen J, Egger B, Ohara N, Zeltner T, Zysset T, et al. Determinants of heptic function in liver cirrhosis in the rat: multivariate analysis. Journal of Clinical Investigation 82: 2069–2076, 1988
Reichen J, Hoilien C, Le M, Jones RH. Decreased uptake of taurocholate and ouabain by hepatocytes isolated from cirrhotic rat liver. Hepatology 7: 67–70, 1987b
Reichen J, Le M. Sinusoidal capillarization is more important than intrahepatic shunting to explain decreased propranolol clearance in liver cirrhotic rats. Abstract. Gastroenterology 84: 1283, 1983
Reichen J, Le M. Verapamil favourably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. Journal of Clinical Investigation 78: 448–455, 1986
Reichen J, Simon FR. Cholestasis. In Arias et al. (Eds) The liver, biology and pathobiology, pp. 785–800, Raven Press, New York, 1982
Renner E, Weitholtz H, Huguenin P, Arnaud MJ, Preisig R. Caffeine: a model compound for measuring liver function. Hepatology 4: 38–46, 1984
Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology 8: 385–401, 1988
Roughton FJW, Forster RE. Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. Journal of Applied Physiology 11: 290–302, 1957
Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications pp. 189–190, Lea & Febiger, Philadelphia, 1989
Royer RJ, Royer-Morrot MJ, Paille F, Barrucand D, Schmitt J, et al. Tianeptine and its main metabolite. Pharmacokinetics in chronic alcoholism and cirrhosis. Clinical Pharmacokinetics 16: 186–191, 1989
Sakiyama R, Pardridge WM, Judd HL. Effects of human cirrhotic serum on oestradiol and testosterone transport into rat brain. Journal of Clinical Endocrinology and Metabolism 54: 1140–1144, 1982
Samson Y, Bernau J, Pappata S, Chatoix C, Baron JC, et al. Cerebral uptake of benzodiazepine measured by positron emission tomography in hepatic encephalopathy. New England Journal of Medicine 316: 414–415, 1987
Saudek F, Moravek J, Modr Z. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test. International Journal of Clinical Pharmacology, Therapy and Toxicology 27: 82–87, 1989
Schafer DF, Fowler JM, Munson PJ, Thakur AK, Waggoner JG, et al. Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. Journal of Laboratory and Clinical Medicine 102: 870–880, 1983
Schenker S, Bergstrom RF, Wolen RL, Lemberger L. Fluoxetine disposition and elimination in cirrhosis. Clinical Pharmacology and Therapeutics 44: 353–359, 1988
Schentag JJ, Cerra FB, Calleri G, Deglopper E, Rose JQ, et al. Age, disease and cimetidine disposition in healthy subjects and chronically ill patients. Clinical Pharmacology and Therapeutics 29: 737–743, 1981
Scott NR, Stambuk D, Chakraborty J, Marks V, Morgan MY. Caffeine clearance and biotransformation in patients with chronic liver disease. Clinical Science 74: 377–384, 1988
Scott NR, Stambuk D, Chakraborty J, Marks V, Morgan MY. The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. British Journal of Clinical Pharmacology 27: 205–213, 1989
Secor JW, Schenker S. Drug metabolism in patients with liver disease. In Stollerman (Ed.) Advances in internal medicine. Vol. 32, pp. 379–406, Year Book Medical Publishers, Chicago 1987
Sherman IA, Pappas SC, Fisher MM. Hepatic microvascular changes associated with development of liver fibrosis and cirrhosis. American Journal of Physiology 258: H460–H465, 1990
Shull HJ, Wilkinson GR, Johnson R, Schenker S. Normal dispersion of oxazepam in acute viral hepatitis and cirrhosis. Annals of Internal Medicine 84: 420–425, 1976
Skak C, Keiding S. Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver 7: 155–162, 1987
Smallwood RH, Mihaly GW, Smallwood RA, Morgan DJ. Effect of a protein binding change on unbound and total plasma concentrations for drugs of intermediate hepatic extraction. Journal of Pharmacokinetics and Biopharmaceutics 16: 529–542, 1988
Smith IL, Ziemniak JA, Bernhard H, Eshelman FN, Martin LE, et al. Ranitidine disposition and systemic availability in hepatic cirrhosis. Clinical Pharmacology and Therapeutics 35: 487–494, 1984
Sonne J, Andreasen PB, Loft S, Dossing M, Andreasen F. Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatology 11: 951–956, 1990
Sonne J, Poulsen HE, Dossing M, Larsen NE, Andreasen PB. Cimetidine clearance and bioavailability in hepatic cirrhosis. Clinical Pharmacology and Therapeutics 29: 191–197, 1981
Sotaniemi EA, Niemela O, Risteli L, Stenback F, Pelkonen O, et al. Fibrotic process and drug metabolism in alcoholic liver disease. Clinical Pharmacology and Therapeutics 40: 46–55, 1986
Spahn H, Reuter K, Mutschier E, Gerok W, Knauf H. Pharmacokinetics of amiloride in renal and hepatic disease. European Journal of Clinical Pharmacology 33: 493–498, 1987
Tillement JP, Lhoste F, Giudiccelli JF. Disease and drug protein binding. Clinical Pharmacokinetics 3: 144–154, 1978
Trouvin J-H, Farinotti R, Haberer J-P, Servin F, Chauvin M, et al. Pharmacokinetics of midazolam in anaesthetised cirrhotic patients. British Journal of Anaesthesia 60: 762–767, 1988
Tygstrup N. Determination of hepatic galactose elimination capacity after a single intravenous injection in man. Acta Physiologica Scandinavica 58: 162–172, 1963
Tygstrup N, Winkler K. Galactose blood clearance as a measure of hepatic blood flow. Clinical Science 17: 1–9, 1958
van Harten J, van Brummelen P, Wilson JHP, Lodweijks MTM, Breimer DD. Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis and intravenous and oral administration. European Journal of Clinical Pharmacology 34: 387–394, 1988
Varin F, Huet PM. Hepatic microcirculation in the perfused cirrhotic rat liver. Journal of Clinical Investigation 76: 1904–1912, 1985
Verbeeck RK, Patwardhan RV, Villeneuve J-P, Wilkinson GR, Branch RA. Furosemide disposition in cirrhosis. Clinical Pharmacology and Therapeutics 31: 719–725, 1982
Vesell ES. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clinical Pharmacology and Therapeutics 26: 275–286, 1979
Vesell ES, Page JG. Genetic control of drug levels in man. Science 161: 72–73, 1968
Villeneuve JP, Fortunet-Fouin H, Arsene D. Cimetidine kinetics and dynamics in patients with severe liver disease. Hepatology 3: 923–927, 1983
Villeneuve JP, Huet PM. Microcirculatory abnormalities in liver disease. Hepatology 7: 186–187, 1987
Villeneuve JP, Rocheleau F, Raymond G. Triamterene kinetics and dynamics in cirrhosis. Clincial Pharmacology and Therapeutics 35: 831–837, 1984
Villeneuve JP, Thibeault MJ, Ampelas M, Fortunet-Fouin H, Lamarre L, et al. Drug disposition in patients with HBsAg-positive chronic liver disease. Digestive Diseases and Sciences 32: 710–714, 1987
Villeneuve JP, Verbeeck RK, Wilkinson GR, Branch RA. Furosemide kinetics and dynamics in patients with cirrhosis. Clinical Pharmacology and Therapeutics 40: 14–20, 1986
Vine JP, Caucanas JP, Cales P, Suduca JM, Voigt JJ, et al. Effect of propranolol on metabolic activity of the liver in patients with alcoholic cirrhosis. Journal of Hepatology 7: 186–192, 1988
Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, et al. The erythromycin breath test as a predictor of cyclosporin blood levels. Clinical Pharmacology and Therapeutics 48: 120–129, 1990
Watson RGP, Bastain W, Larkin KA, Hayes JR, McAinsh JA. A comparative pharmacokinetic study of conventional propranolol and a long acting preparation of propranolol in patients with cirrhosis and normal controls. British Journal of Clinical Pharmacology 24: 527–535, 1987
Watt G, White NJ, Padre L, Ritter W, Fernando MT, et al. Praziquantel pharmacokinetics and side effects in schistosoma japonicum-infested patients with liver disease. Journal of Infectious Diseases 157: 530–535, 1988
Wensing G, Ohnhaus EE, Hoensch HP. Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease. Clinical Pharmacology and Therapeutics 47: 693–705, 1990a
Wensing G, Sabra R, Branch RA. Renal and systemic hemodynamics in experimental cirrhosis in rats: relation to hepatic function. Hepatology 12: 13–19, 1990b
Wiegard BD, Ketterer SG, Rapaport E. The use of indocyanine green for the evaluation of hepatic function and blood flow in man. American Journal of Digestive Diseases 5: 427–436, 1960
Wilkinson GR. Influence of hepatic disease on pharmacokinetics. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., pp. 116–138, Applied Therapeutics, Spokane 1986
Wilkinson GR. Clearance approaches in pharmacology. Pharmacological Reviews 39: 1–47, 1987
Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green. Clinical Pharmacology and Therapeutics 20: 290–299, 1976
Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clinical Pharmacology and Therapeutics 21: 301–309, 1977
Williams RL, Upton RA, Cello JP, Jones RM, Blitstein M, et al. Naproxen disposition in patients with alcoholic cirrhosis. European Journal of Clinical Pharmacology 27: 291–296, 1984
Witassek F, Bircher J, Huguenin P, Preisig R. Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver. Hepatology 3: 415–422, 1983
Withrington PG, Richardson PDI. Hepatic hemodynamics and microcirculation. In Thurman et al. (Eds) Regulation of hepatic metabolism — intra and intercellular compartments, pp. 27–53, Plenum Press, New York, 1986
Wood AJJ, Kornhauser DM, Wilkinson GR, Shand DG, Branch RA. The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clinical Pharmacokinetics 3: 478–487, 1978
Wood AJJ, Villeneuve JP, Branch RA, Rogers LW, Shand DG. Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat. Gastroenterology 76: 1358–1362, 1979
Wood LJ, Massie D, McLean AJ, Dudley FJ. Renal sodium retention in cirrhosis: tubular site and relation to hepatic dysfunction. Hepatology 8: 831–836, 1988
Young CJ, Daneshmend TK, Roberts CJC. Effects of cirrhosis and aging in the elimination and bioavailability of ranitidine. Gut 23: 819–832, 1982
Zaki AEO, Ede RJ, Davis M, Williams R. Experimental studies of blood brain barrier permeability in acute hepatic failure. Hepatology 4: 359–363, 1984
Zeeh J, Lange H, Bosch J, Pohl S, Loesgen H, et al. Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology 95: 749–759, 1988
Zeneroli ML. Hepatic encephalopathy. Experimental studies in a rat model of fulminant hepatic failure. Journal of Hepatology 1: 301–312, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McLean, A.J., Morgan, D.J. Clinical Pharmacokinetics in Patients with Liver Disease. Clin. Pharmacokinet. 21, 42–69 (1991). https://doi.org/10.2165/00003088-199121010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199121010-00004